Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kite First Off The Blocks For EU CAR-T Filing

Executive Summary

Kite Pharma may have been pipped to the post to be first with a CAR-T product at the US FDA, but it has sneaked in the first EU filing courtesy of PRIME for axicabtagene ciloleucel.

Advertisement

Related Content

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
What's Gilead Getting From Kite For Nearly $12bn?
Novartis CAR-T AdComm Was Smooth Sailing, But Will That Be An Anomaly?
CAR-T Companies Hang Onto Novartis' Coat-Tails After Historic FDA Panel Vote
Much Anticipated JULIET Data Show Novartis Playing Catch-Up On CAR-T Manufacturing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099241

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel